Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.

Authors

null

Kavita M. Dhodapkar

Yale Univ, New Haven, CT

Kavita M. Dhodapkar, Chandra S Boddupalli, Noffar Bar, Krishna Kadaveru, Michael Krauthammer, Natapol Pornputtapong, Zifeng Mai, Stephan Ariyan, Deepak Narayan, Harriet M. Kluger, Yanhong Deng, Rakesh Verma, Rituparna Das, Antonella Bacchiocchi, Ruth Halaban, Mario Sznol, Madhav V. Dhodapkar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Phamacodynamic Markers

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 3)

DOI

10.1200/JCO.2017.35.7_suppl.3

Abstract #

3

Poster Bd #

A3

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).

A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).

First Author: Peter Joel Hosein

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.

Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.

First Author: C. Marcela Diaz-Montero